

1 **Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against**  
2 **variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37**

3

4 Juan Manuel Carreño<sup>1</sup>, Hala Alshammary<sup>1</sup>, Gagandeep Singh<sup>1</sup>, Ariel Raskin<sup>1</sup>, Fatima Amanat<sup>1,2</sup>, Angela  
5 Amoako<sup>1</sup>, Ana Silvia Gonzalez-Reiche<sup>2,6</sup>, Adriana van de Guchte<sup>6</sup>, PARIS study group<sup>1</sup>, Komal Srivastava<sup>1</sup>,  
6 Emilia Mia Sordillo<sup>3</sup>, D. Noah Sather<sup>4,5</sup>, Harm van Bakel<sup>6,7,\*</sup>, Florian Krammer<sup>1,3,\*</sup> and Viviana Simon<sup>1,3, 8,9\*</sup>

7 <sup>1</sup>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

8 <sup>2</sup>Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

9 <sup>3</sup>Department of Pathology, Molecular and Cell Based Medicine Icahn School of Medicine at Mount Sinai,  
10 New York, NY, USA

11 <sup>4</sup>Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United  
12 States

13 <sup>5</sup>Department of Pediatrics, University of Washington, Seattle, WA, United States

14 <sup>6</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY  
15 10029, USA;

16 <sup>7</sup>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai,  
17 New York, NY 10029, USA

18 <sup>8</sup>Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New  
19 York, NY, USA

20 <sup>9</sup>The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New  
21 York, NY, USA

22

23 \*To whom correspondence should be addressed: [harm.vanbakel@mssm.edu](mailto:harm.vanbakel@mssm.edu),  
24 [florian.krammer@mssm.edu](mailto:florian.krammer@mssm.edu), [viviana.simon@mssm.edu](mailto:viviana.simon@mssm.edu)

25

26 PARIS study group (in alphabetical order, Study group/Consortium): Mahmoud Awawda, Radhika Banu,  
27 Katherine Beach, Carolina Bermúdez-González, Dominika Bielak, Liyong Cao, Rachel Chernet, Parnavi  
28 Desai, Shelcie Fabre, Emily. D. Ferreri, Daniel Floda, Charles Gleason, Hisaaki Kawabata, Zenab Khan, Dr.  
29 Giulio Kleiner, Dr. Denise Jarczyszak, Julia Matthews, Wannu Mendez, Dr. Lubbertus CF Mulder, Kayla Dr.  
30 Alberto E Paniz-Mondolfi, Russo, Ashley Salimbangon, Dr. Miti Saksena, A. Shin, Levy Sominsky, Johnston  
31 Tcheou

## 32 Abstract

33 Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have  
34 been developed.<sup>1</sup> However, the emergence of viral variants that are more infectious than the earlier  
35 SARS-CoV-2 strains is concerning.<sup>2</sup> Several of these viral variants have the potential to partially escape  
36 neutralizing antibody responses warranting continued immune-monitoring. Here, we tested a number of  
37 currently circulating viral variants of concern/interest, including B.1.526 (Iota), B.1.1.7+E484K (Alpha),  
38 B.1.351 (Beta), B.1.617.2 (Delta) and C.37 (Lambda) in neutralization assays using a panel of post-mRNA  
39 vaccination sera. The assays were performed with authentic SARS-CoV-2 clinical isolates in an assay that  
40 mimics physiological conditions. We found only small decreases in neutralization against B.1.526 and an  
41 intermediate phenotype for B.617.2. The reduction was stronger against a sub-variant of C.37, followed  
42 by B.1.351 and B.1.1.7+E484K. C.37 is currently circulating in parts of Latin America<sup>3</sup> and was detected in  
43 Germany, the US and Israel. Of note, reduction in a binding assay that also included P.1, B.1.617.1  
44 (Kappa) and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2  
45 vaccines may remain effective against these viral variants of concern/interest and that spike binding  
46 antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity.

## 47 Introduction

48 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China  
49 and has since then caused the coronavirus disease 2019 (COVID-19) pandemic. Vaccines were developed  
50 and distributed in record speed with emergency use authorizations as early as December 2020 (in the  
51 US). Coronaviruses are an exception among RNA viruses because their replication machinery possesses  
52 proofreading activity.<sup>4</sup> It was, therefore, expected that they would evolve slower than other RNA  
53 viruses. The emergence of variant viruses, first in Europe in the summer of 2020<sup>5-7</sup> - including in minks in  
54 Denmark - and then in late 2020 in the UK<sup>8</sup>, South Africa<sup>9</sup> and Brazil<sup>10</sup> was a surprising event. Since the  
55 detection of these first variants, several other variants of interest (Vols) and variants of concern (VoCs)  
56 have spread locally as well as globally. These include B.1.526 (Iota) which emerged in New York City and  
57 comprises three different sub-lineages<sup>11,12</sup>, B.1.427/B.1.429 (Epsilon) which emerged in California,<sup>13</sup> C.37  
58 (Lambda) which emerged in Peru,<sup>3</sup> B.1.617.2 (Delta) and B.1.617.1 (Kappa) which emerged in India,<sup>14</sup>  
59 B.1.1.7+E484K (Alpha) which was detected in several countries, as well as A.23.1 which was first  
60 detected in Uganda.<sup>15</sup> Several of these lineages are in decline, including B.1.526 and B.1.427/B.1.429  
61 while others such as B.1.617.2 are increasing in prevalence. Many of these variants display extensive  
62 changes in the N-terminal domain (NTD) and/or the receptor binding domain (RBD) of spike, both of  
63 which harbor neutralizing epitopes. In addition, several of these variants also contain additional  
64 mutations in their spike gene that may enhance affinity to human angiotensin converting enzyme 2  
65 (ACE2).<sup>16</sup> These changes may impact negatively on binding and neutralization by vaccine-induced  
66 antibodies, which are discussed as mechanistic correlates of protection.<sup>17,18</sup> It is, therefore, important to  
67 monitor neutralizing and binding activity of sera from vaccinees against these variants.

68 Here, we tested the neutralizing activity of a panel of 30 post mRNA SARS-CoV-2 vaccination  
69 sera against the three B.1.526 sublineages, B.1.1.7+E484K, B.1.617.2, B.1.351 and a C.37 sub-variant  
70 using a microneutralization assay. This assay was designed to allow for multicycle replication with  
71 sera/antibodies being present in the overlay at all times to better mimic physiological conditions.<sup>19</sup> In  
72 addition, we performed binding assays against recombinant RBD and full-length spike proteins of several  
73 Vols and VoCs.

## 74 Results

75 First, we assessed the neutralizing activity of 30 post-vaccination serum samples from  
76 individuals vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech). This panel of sera is  
77 used by the NIAID SARS-CoV-2 Assessment of Viral Evolution (SAVE) 'in vitro' group, which is part of the  
78 US Department of Health and Human Services (HHS) SARS-CoV-2 Interagency Group (SIG), to determine  
79 the immune escape of different VoCs and Vols.<sup>20</sup> The viruses tested in this study include the wild type  
80 WA1 isolate as well as clinical isolates derived from nasopharyngeal swabs obtained from patients  
81 diagnosed with COVID-19 at the Mount Sinai Health System in New York City, representing B.1.526 (no  
82 change in RBD), B.1.526 (E484K), B.1.526 (S477N), B.1.1.7+E484K, B.1.351, B.1.617.2 and a subvariant of  
83 C.37 (**Supplementary Table 1, Supplemental Figure 1**). The C.37 subvariant contained additional  
84 changes compared to the consensus sequence including a large 13 amino acid deletion instead of G75V  
85 and T76I NTD substitutions and an additional E471Q substitution in the RBD. The panel of post-  
86 vaccination sera (**Supplementary Table 2**) was tested against these seven viruses in a well-established  
87 neutralization assay.<sup>19</sup> In this assay, 60 tissue culture infectious doses of virus per well are pre-incubated  
88 with the respective serum dilutions for one hour. The serum/virus mix is then used to infect Vero.E6  
89 cells. After the infection step, the cell culture medium is replaced with fresh medium containing the  
90 respective concentration of serum. The assay allows, therefore, for multicycle replication of the test  
91 virus in the continuous presence of test serum, which recapitulates infection conditions *in vivo*.

92 The microneutralization assays showed only modest reductions in neutralizing activity against  
93 the three B.1.526 variants compared to the wild type WA1 isolate (**Figure 1**). The geometric mean titer  
94 (GMT) of neutralization of the three B.1.526 sublineages was reduced by 1.4-fold (ancestral B.1.526),  
95 1.8-fold (E484K) and 2.3-fold (S477N), respectively. Reduction in neutralizing activity against the  
96 B.1.617.2 isolate was moderate with 3-fold change compared to WA1. A more pronounced drop in  
97 neutralizing activity was seen with the B.1.1.7+E484K isolate (3.8-fold). As expected and reported  
98 before, an even stronger decrease in neutralization (4.2-fold) was found against the B.1.351 isolate.  
99 However, the greatest reduction in GMT (4.6-fold) was observed against a C.37 variant isolate. Of note,  
100 as explained above, virus isolate PV29369 carries additional substitutions/deletions in spike (see  
101 **Supplemental Table 1**) compared to the majority of circulating C.37.

102 We next determined antibody-binding activity against variant RBDs and spike proteins. The fold-  
103 reduction in binding against variant RBDs from B.1.1.7, P.1 and B.1.351 was negligible with a maximum  
104 reduction of 1.6-fold against the B.1.351 RBD (**Figure 2A and B**). Similarly, reduction in binding to  
105 B.1.1.7, B.1.351, P.1, B.1.617.1 and A.23.1 spike proteins was minimal, again with B.1.351 showing the  
106 strongest impact and a 1.4-fold reduction (**Figure 2C and D**).

## 107 Discussion

108 Monitoring the effectiveness of vaccination in the context of evolving viral variants is of great  
109 public health concern for control of the COVID-19 pandemic. Indeed, neutralizing antibodies play a  
110 major role in protection from COVID-19, as shown both in animal models as well as in humans.<sup>17,18,21-23</sup> It  
111 is, therefore, important to continuously monitor emerging variants and their impact on neutralizing  
112 activity of post-vaccination serum. Our data show a spectrum of neutralizing activities against a panel of  
113 Vols and VoCs. The least negative impact on neutralization was seen for B.1.526 variant, which is  
114 reasonable since this isolate has very few changes in the spike protein (T95I, D253G and D614G)  
115 compared to the wild type WA1 isolate. The impact was higher for the B.1.526 isolates that carry, in

116 addition, E484K or S477N substitutions in the RBD. Interestingly, S477N exerted a stronger impact than  
117 E484K, which was surprising given the strong reduction caused by introduction of E484K into the WA1  
118 wild type backbone.<sup>24</sup> However, S477N has also been described as escape mutation.<sup>25</sup> The reduction in  
119 neutralization against B.1.617.2 was moderate, which aligns well with the preserved vaccine  
120 effectiveness against this variant.<sup>26,27</sup> The combination of B.1.1.7 (which already harbors two deletions in  
121 the NTD) with E484K led to a substantial reduction in neutralizing activity. However, although  
122 B.1.1.7+E484K emerged several times independently, it does not seem to spread well – potentially due  
123 to the detrimental effect that the E484K mutation can have on binding affinity to human ACE2.<sup>16</sup> As  
124 expected and already shown by several publications,<sup>28-33</sup> neutralizing activity to B.1.351 was strongly  
125 reduced likely due to the three changes in RBD and extensive changes in the NTD. Interestingly,  
126 neutralizing activity was even more reduced for the local isolate of C.37 used in the current study which  
127 has more extensive changes in the NTD ( $\Delta 63-75$ ,  $\Delta 246-252$ ) and the RBD (L452Q, E471Q, F490S)  
128 compared to the predominant C.37 variant (NTD: G75V, T76I,  $\Delta 246-252$ ; RBD: L452Q, F490S).<sup>3</sup> While  
129 there was a strong reduction in neutralizing activity of post-vaccination sera against this variant, all 30  
130 sera retained at least partial neutralization activity against this C37 variant virus which may indicate that  
131 – similar to B.1.351<sup>34</sup> – mRNA vaccines will remain effective against these Vols. Of note, the additional  
132 changes in the local C.37 isolate likely contribute to the immune evasion phenotype shown here and  
133 should be seen as worst case scenario for the C.37 variant.

134 Another interesting finding was that the reduction in binding activity to variant RBD and spike proteins  
135 was negligible. However, while neutralization activity is mostly dependent on only a few epitopes in the  
136 RBD and NTD, many more binding epitopes exist on the spike,<sup>16</sup> which may explain our findings.  
137 Interestingly, a recent study found even better correlation between binding activity and vaccine  
138 effectiveness than for neutralizing activity and vaccine effectiveness.<sup>17</sup> This may indicate that binding  
139 antibodies – even if they lack neutralizing activity – are involved in protection. It is well known that non-  
140 neutralizing antibodies raised upon infection or vaccination by ebolavirus or influenza viruses, can be  
141 protective via Fc-mediated effector functions.<sup>35-38</sup> Future studies are needed to establish if this is also  
142 the case for SARS-CoV-2. However, the finding that the drop in binding activity is negligible even against  
143 spike proteins from variants with extensive changes like B.1.351 is reassuring in that context.

144

## 145 **Materials and Methods**

146 **Cells and SARS-CoV-2 isolates.** Vero.E6 cells were cultured in Dulbecco's Modified Eagles Medium  
147 (DMEM, Corning) containing 10% fetal bovine serum (FBS, Corning) supplemented with 100 U/ml  
148 penicillin, 100  $\mu$ g/ml streptomycin (Gibco). Nasopharyngeal swab specimens were collected as part of  
149 the routine SARS-CoV-2 surveillance conducted by the Mount Sinai Pathogen Surveillance program (IRB  
150 approved, HS#13-00981). Specimens were selected for viral culture on Vero-E6 cells based on the  
151 complete viral genome sequence information.<sup>39</sup> Viruses were grown in Vero.E6 cells for 4-6 days; the  
152 supernatant was clarified by centrifugation at 4,000 g for 5 minutes and aliquots were frozen at -80°C  
153 for long term use. Expanded viral stocks were sequence-verified and titered on Vero.E6 cells prior to use  
154 in microneutralization assays.

155 **Phylogeny of SARS-CoV-2 lineages.** The phylogenetic relationships of the SARS-CoV-2 isolates from the  
156 Pathogen Surveillance Program of the Mount Sinai Health System are depicted in a New York focused

157 background from GISAID. The timed tree was built with [nextstrain.org/sars-cov-2](https://nextstrain.org/sars-cov-2). PANGO lineages are  
158 depicted for the Vols and VoCs used in the neutralization assays.

159 **Post vaccination serum samples.** A panel of 30 post-vaccination sera was generated for use and  
160 distribution by BEI Resources for the NIAID SAVE “*in vitro*” group (**Supplementary Table 2**). Briefly, 30  
161 participants enrolled in the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) study  
162 (reviewed and approved by the Mount Sinai Hospital Institutional Review Board; IRB-20-03374) were  
163 invited to provide additional serum samples after receiving their second mRNA vaccine dose. All  
164 specimens were coded prior to processing, banking and sharing with BEI Resources. 15 participants had  
165 received two doses of the mRNA-1273 (Moderna) and 15 participants had received two doses of the  
166 BNT162b2 (Pfizer/BioNTech). The majority of participants were naïve prior to vaccination with 4-5  
167 COVID-19 survivors being included each vaccine group.

168 **ELISA.** Antibody titers in sera from vaccinees were determined by a research grade enzyme-linked  
169 immunosorbent assay (ELISA) using recombinant versions of the receptor binding domain (RBD) and the  
170 spike (S) of wild type SARS-CoV-2 and variant viruses (RBD: WT/Wuhan-1, B.1.1.7, B.1.351, P.1; spike:  
171 WT/Wuhan-1, B.1.1.7, B.1.351, P.1, B.1.617.1, A.23.1). Briefly, 96-well microtiter plates (Thermo Fisher)  
172 were coated with 50 µl/well of recombinant protein (2 µg/ml) overnight at 4 °C. Plates were washed  
173 three times with phosphate-buffered saline (PBS; Gibco) supplemented with 0.1% Tween-20 (PBS-T;  
174 Fisher Scientific) using an automatic plate washer (BioTek). For blocking, PBS-T containing 3% milk  
175 powder (American Bio) was used. After 1-hour incubation at room temperature (RT), blocking solution  
176 was removed and initial dilutions of heat-inactivated sera (in PBS-T 1%-milk powder) were added to the  
177 plates, followed by 2-fold serial dilutions. After 2-hour incubation, plates were washed three times with  
178 PBS-T and 50 µl/well of the pre-diluted secondary antibody anti-human IgG (Fab-specific) horseradish  
179 peroxidase antibody (produced in goat; Sigma, A0293) diluted 1:3,000 in PBS-T containing 1% milk  
180 powder were added. After 1-hour incubation at RT, plates were washed three times with PBS-T and  
181 SigmaFast o-phenylenediamine dihydrochloride (Sigma) was added (100 µl/well) for 10min, followed by  
182 addition of 50 µl/well of 3 M hydrochloric acid (Thermo Fisher) to stop the reaction. Optical density was  
183 measured at a wavelength of 490 nm using a plate reader (BioTek). Area under the curve (AUC) values  
184 were calculated and plotted using GraphPad Prism 7.

185 **Microneutralization assay.** Sera from vaccinees were used to assess the neutralization of wild type  
186 SARS-CoV-2 and selected Vols and VoCs (**Supplementary Table 1**). All procedures were performed in the  
187 Biosafety Level 3 (BSL-3) facility at the Icahn School of Medicine at Mount Sinai following standard safety  
188 guidelines. Remdesivir was used as a control for wild type and variant viruses to monitor assay variation.  
189 The day before infection, Vero E6 cells were seeded in 96-well high binding cell culture plates (Thermo  
190 Fisher) at a density of 20,000 cells/well in complete Dulbecco’s Modified Eagle Medium (cDMEM). After  
191 heat inactivation of sera (56°C for 1 hour), serum samples were serially diluted (3-fold) in minimum  
192 essential media starting at 1:10. For dilutions of sera, infection media consisting of minimum essential  
193 media (MEM, Gibco) supplemented with 2 mM L-glutamine, 0.1% sodium bicarbonate (w/v, Gibco),  
194 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco), 100 U/ml penicillin,  
195 100 µg/ml streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals) was used. Vero E6  
196 cells were seeded in 96-well high binding cell culture plates (Thermo Fisher) at a density of 20,000  
197 cells/well in complete Dulbecco’s Modified Eagle Medium (cDMEM). On the next day, sera dilutions  
198 were incubated with 1,000 tissue culture infectious dose 50 (TCID50) of wt USA-WA1/2020 SARS-CoV-2  
199 or the corresponding variant virus for 1 hour at RT, followed by transfer of 120µl of virus-sera mix to

200 Vero-E6 plates. Infection was led to proceed for 1 hour at 37°C and inoculum was removed. 100 µl/well  
201 of the corresponding antibody dilutions plus 100µl/well of infection media supplemented with 2% fetal  
202 bovine serum (Gibco) were added to the cells. Plates were incubated for 48h at 37°C.

203 For staining of the nucleoprotein antigen, cells were fixed by addition of 150 µl/well of a 10%  
204 formaldehyde solution and incubated overnight at 4°C. Fixed cell monolayers were washed with PBS  
205 (Gibco) and permeabilized with 150 µl/well of PBS, 0.1% Triton X-100 for 15 min at RT. Permeabilization  
206 solution was removed, plates were washed with 200 µl/well of PBS twice and 200 µl/well of blocking  
207 solution consisting of PBS 3% milk (American Bio) were added for 1 h at RT. Blocking solution was  
208 removed and 100 µl/well of mAb 1C7 (anti-SARS nucleoprotein antibody produced in house) diluted in  
209 PBS 1% milk (American Bio) at a 1:4000 dilution were added for 1 h at RT. Primary antibody was  
210 removed and plates were washed with 200 µl/well of PBS twice, followed by addition of 100 µl/well of  
211 goat anti-mouse IgG-HRP (Rockland Immunochemicals) diluted in PBS 1% milk (American Bio) 1:3000.  
212 After 1 hour incubation, antibody solution was removed, plates were washed twice with PBS and  
213 100 µl/well of o-phenylenediamine dihydrochloride (Sigmafast OPD; Sigma-Aldrich) were added for 10  
214 min at RT. The reaction was stopped by addition of 50 µl/well of HCl 3M (Thermo Fisher Scientific).  
215 Optical density (OD) was measured (490 nm) with a microplate reader (Synergy H1; Biotek). Initial  
216 subtraction of background and calculation of the percentage of neutralization with respect to the “virus  
217 only” control was done in excel. A non linear regression curve fit analysis, using Prism 9 software  
218 (GraphPad), was performed to calculate the inhibitory dilution 50% (ID<sub>50</sub>), using top and bottom  
219 constraints of 100% and 0% respectively.

## 220 **Acknowledgments**

221 We would like to thank the study participants for their generosity and willingness to participate in  
222 longitudinal COVID19 research studies. None of this work would be possible without their contributions.  
223 We would like to thank Dr. Randy A. Albrecht for oversight of the conventional BSL3 biocontainment  
224 facility, which makes our work with live SARS-CoV-2 possible. We are also grateful for Mount Sinai’s  
225 leadership during the COVID-19 pandemic. We want to especially thank Drs. Peter Palese, Carlos  
226 Cordon-Cardo, Dennis Charney, David Reich and Kenneth Davis for their support. This work is part of the  
227 PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC)  
228 contract 75N93019C00051. This work was also partially funded by the Centers of Excellence for  
229 Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), and by the generous  
230 support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384);  
231 and by anonymous donors. Finally, this effort was also supported by the Serological Sciences Network  
232 (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health,  
233 under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication  
234 does not necessarily reflect the views or policies of the Department of Health and Human Services, nor  
235 does mention of trade names, commercial products or organizations imply endorsement by the U.S.  
236 Government.

237

## 238 **Conflict of Interest Statement**

239 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2  
240 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor.  
241 Viviana Simon and Fatima Amanat are also listed on the serological assay patent application as co-

242 inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2.  
243 Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer,  
244 Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-  
245 CoV-2.  
246

247 **References**

- 248 1 Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516-527, doi:10.1038/s41586-  
249 020-2798-3 (2020).
- 250 2 Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol*  
251 **19**, 409-424, doi:10.1038/s41579-021-00573-0 (2021).
- 252 3 Romero, P. E. *et al.* The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America.  
253 *medRxiv*, 2021.2006.2026.21259487, doi:10.1101/2021.06.26.21259487 (2021).
- 254 4 Denison, M. R., Graham, R. L., Donaldson, E. F., Eckerle, L. D. & Baric, R. S. Coronaviruses: an  
255 RNA proofreading machine regulates replication fidelity and diversity. *RNA Biol* **8**, 270-279,  
256 doi:10.4161/rna.8.2.15013 (2011).
- 257 5 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases  
258 Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827.e819, doi:10.1016/j.cell.2020.06.043 (2020).
- 259 6 Thomson, E. C. *et al.* Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading  
260 antibody-mediated immunity. *Cell*, doi:10.1016/j.cell.2021.01.037 (2021).
- 261 7 Larsen, H. D. *et al.* Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers  
262 associated with community spread, Denmark, June to November 2020. *Euro Surveill* **26**,  
263 doi:10.2807/1560-7917.ES.2021.26.5.210009 (2021).
- 264 8 PHE.  
265 ([https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/959426/Variant\\_of\\_Concern\\_VOC\\_202012\\_01\\_Technical\\_Briefing\\_5.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf), 2021).
- 267 9 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-  
268 related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.  
269 *medRxiv*, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640 (2020).
- 270 10 Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.  
271 *Science* **372**, 815-821, doi:10.1126/science.abh2644 (2021).
- 272 11 Thompson, C. N. *et al.* Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2  
273 B.1.526 Variant - New York City, New York, January 1-April 5, 2021. *MMWR Morb Mortal Wkly*  
274 *Rep* **70**, 712-716, doi:10.15585/mmwr.mm7019e1 (2021).
- 275 12 Annavajhala, M. K. *et al.* A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New  
276 York. *medRxiv*, doi:10.1101/2021.02.23.21252259 (2021).
- 277 13 McCallum, M. *et al.* SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.  
278 *Science*, doi:10.1126/science.abi7994 (2021).
- 279 14 Kumar, S. Second wave of COVID-19: Emergency situation in India. *J Travel Med*,  
280 doi:10.1093/jtm/taab082 (2021).
- 281 15 Bugembe, D. L. *et al.* A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged  
282 and is dominating the current Uganda epidemic. *medRxiv*, 2021.2002.2008.21251393,  
283 doi:10.1101/2021.02.08.21251393 (2021).
- 284 16 Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD,  
285 RBD, and S2. *Cell*, doi:10.1016/j.cell.2021.06.005 (2021).
- 286 17 Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*,  
287 doi:10.1016/j.vaccine.2021.05.063 (2021).
- 288 18 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from  
289 symptomatic SARS-CoV-2 infection. *Nat Med*, doi:10.1038/s41591-021-01377-8 (2021).
- 290 19 Amanat, F. *et al.* An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug  
291 Screening. *Curr Protoc Microbiol* **58**, e108, doi:10.1002/cpmc.108 (2020).
- 292 20 Walensky, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 Variants of Concern in the United States-  
293 Challenges and Opportunities. *JAMA* **325**, 1037-1038, doi:10.1001/jama.2021.2294 (2021).




- 294 21 McMahan, K. *et al.* Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*  
295 **590**, 630-634, doi:10.1038/s41586-020-03041-6 (2021).
- 296 22 Krammer, F. Correlates of protection from SARS-CoV-2 infection. *Lancet* **397**, 1421-1423,  
297 doi:10.1016/S0140-6736(21)00782-0 (2021).
- 298 23 Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nature*  
299 *Medicine*, doi:10.1038/s41591-021-01432-4 (2021).
- 300 24 Jangra, S. *et al.* SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. *Lancet*  
301 *Microbe*, doi:10.1016/S2666-5247(21)00068-9 (2021).
- 302 25 Liu, Z. *et al.* Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum  
303 antibody neutralization. *Cell Host Microbe* **29**, 477-488.e474, doi:10.1016/j.chom.2021.01.014  
304 (2021).
- 305 26 Sheikh, A., McMenamin, J., Taylor, B., Robertson, C. & Collaborators, P. H. S. a. t. E. I. SARS-CoV-  
306 2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.  
307 *Lancet* **397**, 2461-2462, doi:10.1016/S0140-6736(21)01358-1 (2021).
- 308 27 Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *medRxiv*,  
309 2021.2005.2022.21257658, doi:10.1101/2021.05.22.21257658 (2021).
- 310 28 Edara, V. V. *et al.* Infection- and vaccine-induced antibody binding and neutralization of the  
311 B.1.351 SARS-CoV-2 variant. *Cell Host Microbe* **29**, 516-521.e513,  
312 doi:10.1016/j.chom.2021.03.009 (2021).
- 313 29 Wang, P. *et al.* Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody  
314 Neutralization. *bioRxiv*, 2021.2001.2025.428137, doi:10.1101/2021.01.25.428137 (2021).
- 315 30 Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-  
316 induced sera. *Cell* **184**, 2348-2361.e2346, doi:10.1016/j.cell.2021.02.037 (2021).
- 317 31 Planas, D. *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing  
318 antibodies. *Nat Med* **27**, 917-924, doi:10.1038/s41591-021-01318-5 (2021).
- 319 32 Liu, Y. *et al.* Neutralizing Activity of BNT162b2-Elicited Serum. *N Engl J Med* **384**, 1466-1468,  
320 doi:10.1056/NEJMc2102017 (2021).
- 321 33 Wu, K. *et al.* Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *N Engl J Med* **384**,  
322 1468-1470, doi:10.1056/NEJMc2102179 (2021).
- 323 34 Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & Vaccination, N. S. G. f. C.-. Effectiveness of the  
324 BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med*,  
325 doi:10.1056/NEJMc2104974 (2021).
- 326 35 Sapphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C. & Alter, G. Antibody-mediated  
327 protection against Ebola virus. *Nat Immunol* **19**, 1169-1178, doi:10.1038/s41590-018-0233-9  
328 (2018).
- 329 36 Sapphire, E. O. *et al.* Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines  
330 Features that Contribute to Protection. *Cell* **174**, 938-952.e913, doi:10.1016/j.cell.2018.07.033  
331 (2018).
- 332 37 Henry Dunand, C. J. *et al.* Both Neutralizing and Non-Neutralizing Human H7N9 Influenza  
333 Vaccine-Induced Monoclonal Antibodies Confer Protection. *Cell Host Microbe* **19**, 800-813,  
334 doi:10.1016/j.chom.2016.05.014 (2016).
- 335 38 Asthagiri Arunkumar, G. *et al.* Broadly Cross-Reactive, Nonneutralizing Antibodies against  
336 Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against  
337 Lethal Viral Challenge in Mice. *J Virol* **93**, doi:10.1128/JVI.01696-18 (2019).
- 338 39 Gonzalez-Reiche, A. S. *et al.* Introductions and early spread of SARS-CoV-2 in the New York City  
339 area. *Science*, doi:10.1126/science.abc1917 (2020).

340

341

## 342 Figure Legends

343 **Figure 1. Neutralizing activity of post-mRNA vaccination sera against different VoIs and VoCs. A**  
344 Absolute neutralization titers against the respective variant viruses. **B** Fold reduction of neutralization as  
345 compared to the wild type WA1 isolate. A list of specific mutations of the clinical isolates can be found in  
346 Supplementary Table 1.



347

348

349

350

351

352

353

354

355

356

357

358


359

360

361

362

363 **Figure 2. Binding activity of post-mRNA vaccination sera against RBD and spike proteins of different**  
364 **VoIs and VoCs. A and C show absolute area under the curve (AUC) binding values against various RBD**  
365 **and spike proteins, B and D show fold-reduction in binding as compare to Wuhan-1 derived wild type**  
366 **proteins.**



367  
368  
369  
370  
371  
372

373 **Supplementary Table 1.** Information of viral isolates used in microneutralization assays.

374

375

<b>Mutations in NTD and RBD of the Vols and VoCs used in the study</b>					376
<b>Isolate ID</b>	<b>Lineage</b>	<b>RBD substitutions</b>	<b>NTD deletions</b>	<b>NTD substitutions</b>	377
WT	USA-WA1/2020	None	None	None	378
PV24850	B.1.526	None	None	T95I, D253G	379
PV25278	B.1.526.2	S477N	None	T95I, D253G	380
PV26425	B.1.526	E484K	None	T95I, D253G	381
PV27616	B.1.1.7	E484K, N501Y	H69:V70–, Y144–	E154Q	382
PV29995	B.1.617.2	L452R, T478K	E156:F157–	G142D, R158G	383
PV27007	B.1.351	K417N, E484K, N501Y	L241:A243–	D80A, D215G	384
PV29369	C.37	L452Q, E471Q, F490S	T63:G75–, R246:G252–	D253N	385
					386

387

388

389

390

391

392

393

394

395

396

397

398 **Supplementary Table 2.** Sera used in the neutralization assays.

399

400

#	sample	Vaccine #	Serostatus*	Sex	Days after 1st dose	Days after 2 <sup>nd</sup> dose	
401	1	77579	Moderna	neg	Female	30	2
402	2	76350	Moderna	pos	Male	35	7
403	3	26973	Moderna	neg	Female	32	5
404	4	95482	Moderna	neg	Female	31	3
405	5	93764	Moderna	neg	Female	34	9
406	6	38258	Moderna	neg	Male	34	5
407	7	14275	Moderna	pos	Female	30	2
408	8	22686	Moderna	pos	Female	35	5
409	9	80902	Moderna	neg	Female	32	6
410	10	91353	Moderna	pos	Female	32	5
411	11	66902	Moderna	neg	Female	35	10
412	12	47380	Moderna	neg	Female	37	9
413	13	32885	Moderna	neg	Male	31	3
414	14	30756	Moderna	pos	Female	31	3
415	15	72329	Moderna	neg	Male	33	6
416	16	17146	Pfizer	neg	Female	47	22
417	17	35098	Pfizer	neg	Male	20	6
418	18	94525	Pfizer	neg	Male	28	7
419	19	70771	Pfizer	neg	Male	48	27
420	20	13967	Pfizer	neg	Female	29	8
421	21	29021	Pfizer	neg	Female	42	23
422	22	11348	Pfizer	neg	Male	43	22
423	23	67169	Pfizer	neg	Female	46	22
424	24	91699	Pfizer	pos	Female	49	29
425	25	99695	Pfizer	pos	Male	43	21
426	26	58441	Pfizer	pos	Male	43	25
427	27	79044	Pfizer	pos	Female	43	22
428	28	87845	Pfizer	neg	Female	39	20
429	29	48139	Pfizer	neg	Male	29	9
430	30	26461	Pfizer	neg	Female	43	21

431

432 \* Serostatus denotes SARS-CoV-2 antibodies prior to COVID19 vaccination  
433 # Vaccine: mRNA SARS-CoV-2 vaccines Moderna (mRNA-1273) or Pfizer (BNT162b2) were  
434 administered

435

436


437

438

439

440

441 **Supplementary Figure 1: Phylogenetic tree including all patient isolates used in this study.**



442